stockrow
Friday 6 November 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
49.74
0.99
+2.03%
Follow AXGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.66 | 9.81 | 7.18 | 6.69 | |
P/FCF ratio |
115.48 | 378.46 | 223.17 | 0.00 | |
P/Operating CF |
139.83 | 341.19 | 1,092.16 | 496.12 | |
P/B ratio |
4.66 | 9.61 | 6.98 | 11.70 | |
Price to Tangible BV |
4.74 | 9.91 | 7.20 | 12.34 | |
EV/Sales |
7.42 | 9.44 | 6.83 | 6.79 | |
EV/EBITDA |
0.00 | 0.00 | 3,460.14 | 986.66 | |
EV/Operating CF |
69.88 | 157.54 | 104.54 | 1,883.41 | |
EV/FCF |
98.99 | 364.14 | 212.33 | (319.81) | |
Quick Ratio |
10.54 | 4.86 | 5.07 | 3.04 | |
Current Ratio |
12.02 | 6.60 | 7.10 | 5.11 | |
Net Debt/EBITDA |
(107.27) | 23,830.25 | 129.83 | (3.36) | |
Debt/Assets |
3.21% | 5.93% | 7.13% | 30.51% | |
Debt/Equity |
0.04 | 0.07 | 0.08 | 0.52 | |
Asset Turnover |
0.70 | 0.98 | 0.98 | 1.06 | |
Operating CF/Net income |
7.08 | (4.76) | (0.08) | (0.23) | |
Capex/Depreciation |
(0.78) | (0.81) | (1.35) | (0.61) | |
Interest Coverage |
955.00 | (2,156.00) | (4.08) | (5.69) | |
Research and Development Expense of Revenue |
11.80% | 12.32% | 12.23% | 20.66% | |
Selling, General and Administrative Expense of Revenue |
61.75% | 63.45% | 67.53% | 69.79% | |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
11.60% | 12.57% | 11.13% | 27.73% | |
Graham Net Nets |
0.17 | 0.06 | 0.08 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.55%) | (1.46%) | (1.92%) | (1.02%) | |
Free Cash Flow Yield |
0.87% | 0.26% | 0.45% | (0.32%) | |
Revenue per Share |
1.37 | 1.31 | 1.19 | 1.30 | |
Operating CF per Share |
0.30 | 0.14 | 0.03 | 0.07 | |
Capex per Share |
(0.03) | (0.03) | (0.06) | (0.04) | |
Free Cash Flow per Share |
0.27 | 0.10 | (0.03) | 0.02 | |
Cash per Share |
6.35 | 2.13 | 2.01 | 0.99 | |
Shareholders Equity per Share |
8.99 | 4.80 | 4.75 | 2.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.99 | 4.80 | 4.75 | 2.80 | |
Free Cash Flow |
14.87 | 5.47 | (1.40) | 1.08 | |
Working Capital |
401.64 | 170.00 | 158.70 | 96.87 | |
Capital Expenditures |
(1.67) | (1.75) | (2.96) | (1.96) | |
Net Current Asset Value |
383.86 | 151.77 | 140.03 | 27.58 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.03 | 0.05 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
32.39 | 31.08 | 27.30 | 25.14 | |
Average Payables |
30.15 | 25.58 | 21.78 | 24.91 | |
Average Inventory |
44.82 | 42.04 | 40.79 | 37.78 | |
Average Assets |
383.37 | 255.16 | 242.83 | 212.71 | |
Average Common Equity |
308.45 | 184.27 | 175.09 | 116.38 |
Columns are period end dates · fundamentals updated 5 Nov 2026